Evidence map›Paper›PMID 29264191›Full record

ArticleAsian journal of urology2016

Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer.

Takeshi Hirata, Seung Chol Park, Michelle T Muldong, Christina N Wu, Tomonori Yamaguchi, Amy Strasner, Omer Raheem, Hiromi Kumon, Robert L Sah, Nicholas A Cacalano and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Takeshi HirataDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Seung Chol ParkDepartment of Urology, Wonkwang University School of Medicine and Hospital, Iksan, South Korea.
Michelle T MuldongMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Christina N WuMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Tomonori YamaguchiDepartment of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Amy StrasnerMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Omer RaheemDepartment of Urology, University of California, San Diego, La Jolla, CA, USA.
Hiromi KumonDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Robert L SahDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
Nicholas A CacalanoDepartment of Radiation Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
Catriona H M JamiesonMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Christopher J KaneMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Koichi MasudaDepartment of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Anna A KulidjianMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Christina A M JamiesonMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
University of California, San Diego · USOkayama University · JPUniversity of California, Los Angeles · USWonkwang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBone metastasis occurs in up to 90% of men with advanced prostate cancer and leads to fractures, severe pain and therapy-resistance. Bone metastases induce a spectrum of types of bone lesions which can respond differently to therapy even within individual prostate cancer patients. Thus, the special environment of the bone makes the disease more complicated and incurable. A model in which bone lesions are reproducibly induced that mirrors the complexity seen in patients would be invaluable for pre-clinical testing of novel treatments. The microstructural changes in the femurs of mice implanted with PCSD1, a new patient-derived xenograft from a surgical prostate cancer bone metastasis specimen, were determined.

methodsQuantitative micro-computed tomography (micro-CT) and histological analyses were performed to evaluate the effects of direct injection of PCSD1 cells or media alone (Control) into the right femurs of

resultsBone lesions formed only in femurs of mice injected with PCSD1 cells. Bone volume (BV) was significantly decreased at the proximal and distal ends of the femurs (

conclusionPCSD1 cells reproducibly induced bone loss leading to osteolytic lesions at the ends of the femur, and, in contrast, induced aberrant bone formation leading to osteoblastic lesions along the femur shaft. Therefore, the interaction of PCSD1 cells with different bone region-specific microenvironments specified the type of bone lesion. Our approach can be used to determine if different bone regions support more therapy resistant tumor growth, thus, requiring novel treatments.

Indexed as

Bone metastatic prostate cancerBone microenvironmentMicrostructural CTOsteoblastic lesionsOsteolytic lesionsPatient-derived xenograft

Identifiers

PMID29264191
PMCPMC5730873
OpenAlexW2519109844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.